The North American Menopause Society (NAMS) will hold its 2018 Annual Meeting October 3-6 in San Diego, California. The medical community recognizes the NAMS Annual Meeting as a significant event, and yet it is easy to underestimate the meeting’s full importance.

Think about it. Menopause profoundly affects the health and quality of life of about half of the world’s population for about half of their adult lives. Average female life expectancy in the United States and Europe is 82-85 years and the average age of menopause is 51, with symptoms often beginning months or years earlier. Therefore, the average adult life for females is about 60 years, of which about 30 years are spent during and after menopause.

Menopausal and postmenopausal health conditions include the genitourinary syndrome of menopause (GSM), vasomotor symptoms (VMS), osteoporosis and Alzheimer’s disease, all of which have significant health effects for a period of years or the rest of a woman’s life after onset.  

The NAMS Annual Meeting is such an important event because it presents the latest scientific information on advances in addressing the significant unmet medical needs of a vast global population.

The Genitourinary Syndrome of Menopause at NAMS 2018

The agenda items on GSM are of particular interest because recognition of all the health effects of the menopausal reduction in estrogen and other hormones as a syndrome is recent. At NAMS 2018, we are especially looking forward to Plenary Symposium 5 –  Genitourinary Syndrome of Menopause. The symposium will include presentations on “Vaginal Estrogen Safety and Labeling: State of the Science” and a “Review of Lasers for Genitourinary Syndrome of Menopause.”

Addressing the Challenges of Studies in a Menopausal and Postmenopausal Population

Clinical studies in a menopausal and postmenopausal population present an array of unique challenges. For example, in GSM studies one challenge is obtaining endometrial biopsies when required by the protocol for safety reasons. Failure to collect adequate endometrial biopsy specimens is a risk in GSM studies and demands a mitigation strategy.  Potential mitigations to consider include precise training in biopsy techniques, allowing use of a tenaculum or of specific devices that offer the greatest likelihood of success and use of dilators and medications for cervical dilation.

Health Decisions understands the challenges of conducting clinical studies in a menopausal and postmenopausal population. We offer capabilities for studies of treatments for indications including VSM and GSM. To explore how Health Decisions can assist with your program for GSM or other menopausal and postmenopausal indications, please contact us.